Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN   US75886F1075

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2014 11/20/2014 11/21/2014 11/24/2014 11/25/2014 Date
415.25(c) 406(c) 405.25(c) 409.75(c) 413(c) Last
631 129 645 940 890 661 655 780 818 587 Volume
+0.49% -2.23% -0.18% +1.11% +0.79% Change
More quotes
Company
Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company.It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.Regeneron markets medicines for eye diseases, colorectal cancer and a rare inflammatory condition and... 
Sector
Pharmaceuticals
Calendar
12/01 | 07:30amPresentation
Surperformance© rating of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More about the company
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 2 791 M
EBIT 2014 1 142 M
Net income 2014 373 M
Finance 2014 1 084 M
Yield 2014 -
Sales 2015 3 435 M
EBIT 2015 1 620 M
Net income 2015 697 M
Finance 2015 2 163 M
Yield 2015 -
PER 2014 128,73
PER 2015 70,97
EV / Sales 2014 14,7x
EV / Sales 2015 11,6x
Capitalization 41 988 M
More Financials
Latest news on REGENERON PHARMACEUTICALS
2d ago REGENERON PHARMACEUTICALS : Biotech Stocks in Motion - Amgen, Merrimack Pharma, ..
5d ago REGENERON PHARMACEUTICALS : Entry into a Material Definitive Agreement (form 8-K..
5d ago SANOFI : and Regeneron's atopic dermatitis drug receives FDA breakthrough therap..
6d ago Sanofi touts new drugs but diabetes outlook disappoints
6d ago REGENERON PHARMACEUTICALS : Assigned Patent
7d ago REGENERON PHARMACEUTICALS : and Sanofi Announce Positive Results from Phase 2b S..
7d ago REGENERON PHARMACEUTICALS : Patent Application Titled "Methods and Compositions ..
7d ago REGENERON PHARMACEUTICALS : and Sanofi Announce New Results from Six Phase 3 Tri..
11/18 REGENERON PHARMACEUTICALS : Announces EYLEA® (aflibercept) Injection Approved fo..
11/17 NASDAQ 100 MOVERS : Vip, myl
11/12 REGENERON PHARMACEUTICALS : "Methods of Inhibiting Tumor Growth by Antagonizing ..
11/12 REGENERON PHARMACEUTICALS : Patent Issued for Humanized IL-6 and IL-6 Receptor
More news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF